

Supplementary material has been published as submitted. It has not been copyedited or typeset by Scandinavian Journal of Urology.

**eTable 1.** Summary two-by-two table from validation of docetaxel registration in the National Prostate Cancer Register (NPCR). Systematic patient record review of 500 randomly selected men aged < 80 years and with metastases at the time of diagnosis of prostate cancer.

	Docetaxel administration verified in patient record review	Docetaxel administration NOT verified in patient record review	Total
Docetaxel registered in NPCR	151	15	166
Docetaxel NOT registered in NPCR	65	269	334
Total	216	284	500

**eTable 2.** Diagnostic test statistics for counts according to eTable 1. Calculated with R EpiR package (version 2.0.39).

	Point estimates and 95% confidence intervals (CIs)
Apparent prevalence <sup>a</sup>	0.33 (0.29, 0.38)
True prevalence <sup>a</sup>	0.43 (0.39, 0.48)
Sensitivity <sup>a</sup>	0.70 (0.63, 0.76)
Specificity <sup>a</sup>	0.95 (0.91, 0.97)
Positive predictive value <sup>a</sup>	0.91 (0.86, 0.95)
Negative predictive value <sup>a</sup>	0.81 (0.76, 0.85)
Positive likelihood ratio	13.24 (8.03, 21.83)
Negative likelihood ratio	0.32 (0.26, 0.39)
False Test+ proportion for true Diagnosis- <sup>a, b</sup>	0.05 (0.03, 0.09)
False Test- proportion for true Diagnosis+ <sup>a, b</sup>	0.30 (0.24, 0.37)
False Test+ proportion for Test+ <sup>a, b</sup>	0.09 (0.05, 0.14)
False Test- proportion for Test- <sup>a, b</sup>	0.19 (0.15, 0.24)
Correctly classified proportion <sup>a</sup>	0.84 (0.80, 0.87)

<sup>a</sup> Exact confidence intervals. <sup>b</sup> In this study “*Test*” = Treatment with docetaxel registered in the National Prostate Cancer Register (NPCR) and “*Diagnosis*” = Treatment with docetaxel verified by manual patient record review.